Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration

Seenu M. Hariprasad, Lawrence S Morse, Howard Shapiro, Pamela Wong, Lisa Tuomi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7-16.1%) than with less frequent dosing (5.0-6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.

Original languageEnglish (US)
Article number690641
JournalJournal of Ophthalmology
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Macular Degeneration
Visual Acuity
Ranibizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. / Hariprasad, Seenu M.; Morse, Lawrence S; Shapiro, Howard; Wong, Pamela; Tuomi, Lisa.

In: Journal of Ophthalmology, Vol. 2012, 690641, 2012.

Research output: Contribution to journalArticle

@article{3970614f0bd64ada87c08e4f9d903369,
title = "Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration",
abstract = "Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9{\%} to 29.4{\%} of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7-16.1{\%}) than with less frequent dosing (5.0-6.0{\%}). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.",
author = "Hariprasad, {Seenu M.} and Morse, {Lawrence S} and Howard Shapiro and Pamela Wong and Lisa Tuomi",
year = "2012",
doi = "10.1155/2012/690641",
language = "English (US)",
volume = "2012",
journal = "Journal of Ophthalmology",
issn = "2090-004X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration

AU - Hariprasad, Seenu M.

AU - Morse, Lawrence S

AU - Shapiro, Howard

AU - Wong, Pamela

AU - Tuomi, Lisa

PY - 2012

Y1 - 2012

N2 - Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7-16.1%) than with less frequent dosing (5.0-6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.

AB - Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7-16.1%) than with less frequent dosing (5.0-6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.

UR - http://www.scopus.com/inward/record.url?scp=84873867315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873867315&partnerID=8YFLogxK

U2 - 10.1155/2012/690641

DO - 10.1155/2012/690641

M3 - Article

VL - 2012

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

SN - 2090-004X

M1 - 690641

ER -